
MannKind (NASDAQ:MNKD) expects to be profitable and report record revenue in the fourth quarter as it builds on the launch of FUROSCIX ReadyFlow and the pediatric approval of inhaled insulin Afrezza, CEO Michael Castagna said at the Jefferies 2026 Global Healthcare Conference.
Castagna outlined three growth priorities for 2027: expanding commercial sales of FUROSCIX and Afrezza, extending the company’s collaboration with United Therapeutics, and advancing its own inhaled nintedanib program for idiopathic pulmonary fibrosis, or IPF.
FUROSCIX and Afrezza launches
FUROSCIX ReadyFlow was approved in the third quarter, and approximately 75% of FUROSCIX shipments had converted to the new version, Castagna said. About 90% of community prescriptions coming in for the product were already for ReadyFlow, he added.
MannKind acquired FUROSCIX through its acquisition of scPharmaceuticals. Castagna said roughly 90% of sales currently come from patients whose conditions are worsening at home. He identified hospital discharge and the prevention of readmissions as additional opportunities.
For Afrezza, Castagna said approximately one-third of pediatric endocrinologists had already prescribed the product. About one in four Afrezza patients at the end of the third quarter were children, he said, and pediatric market share in the first 90 days of launch was twice that of adults.
Castagna acknowledged softness in the adult Afrezza business after MannKind shifted sales attention toward FUROSCIX during the scPharmaceuticals integration. The company plans to refocus its sales force on adult Afrezza in 2027 while continuing to support the pediatric launch.
MannKind also plans to introduce a two-unit Afrezza cartridge next year and is submitting Inhale IQ, an inhaler adapter intended to track doses and integrate with continuous glucose monitoring, to the Food and Drug Administration, Castagna said.
United Therapeutics collaboration
Castagna said MannKind expects approximately $1 billion in combined manufacturing and royalty revenue from its United Therapeutics relationship between now and 2030. MannKind will be the sole manufacturer of Tyvaso DPI, he said, adding that the product returned to sequential growth in the third quarter.
The companies are also working on ralinepag, a once-daily prostacyclin product. Castagna said he hoped oral ralinepag would receive approval in 2027 and that MannKind expects about $15 million in milestones from its United Therapeutics relationship, along with clinical supply revenue.
IPF trial plans
MannKind plans to advance inhaled nintedanib into the Phase 2 INFLOW-2 trial in the United States and other markets following a meeting with the FDA, Castagna said. The company expects to add about 15 U.S. sites, bringing the study to roughly 100 sites and 153 patients.
The trial was reduced from a planned 220 patients after MannKind decided to focus on twice-daily dosing rather than a four-times-daily regimen. Castagna said the protocol changes slowed enrollment this year, but the company hopes adding U.S. sites will help bring a data readout forward to early 2028.
In the earlier Phase 1b INFLOW-1 study, none of the 27 patients with IPF discontinued treatment, Castagna said. He added that 60% reported no increase in cough and 30% reported a mild cough. The Phase 2 study will assess efficacy as well as tolerability.
About MannKind (NASDAQ:MNKD)
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).
